Toll-like receptor-9 agonists increase cyclin D1 expression partly through activation of activator protein-1 in human oral squamous cell carcinoma cells

Cancer Science

Volumn 103, Issue 11, 2012, Pages 1938-1945

  Min, Ruan ^a   Siyi, Li ^a   Wenjun, Yang ^a   Shengwen, Liu ^a   Ow, Andrew ^b   Lizheng, Wang ^a   Chenping, Zhang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CPG OLIGODEOXYNUCLEOTIDE; CYCLIN D1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUCIFERASE; MESSENGER RNA; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; TRANSCRIPTION FACTOR AP 1;

ARTICLE; CARCINOMA CELL; CELL PROLIFERATION; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUTH SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; CYCLIN D1; CYCLIN-DEPENDENT KINASE 4; G1 PHASE; HUMANS; MOUTH NEOPLASMS; NF-KAPPA B; OLIGODEOXYRIBONUCLEOTIDES; RNA, MESSENGER; S PHASE; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 9; TRANSCRIPTION FACTOR AP-1;

EID: 84868198340     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02394.x     Document Type: Article

References (39)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics. CA Cancer J Clin 2006; 56: 106-30.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Globocan 2008, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10 Internet. Lyon, France: International Agency for Research on Cancer, 2010. Available from URL: http://globocan.iarc.fr.
3. Scully C, Bagan J. Oral squamous cell carcinoma overview. Oral Oncol 2009; 45: 301-8.
4. Mignogna MD, Fedele S, Lo Russo L, Lo Muzio L, Bucci E. Immune activation and chronic inflammation as the cause of malignancy in oral lichen planus: is there any evidence? Oral Oncol 2004; 40: 120-30.
5. Waldron CA, Shafer WG. Leukoplakia revisited: a clinicopathologic study 3256 oral leukoplakias. Cancer 1975; 36: 1386-92.
6. Sigurgeirsson B, Lindelöf B. Lichen planus and malignancy. An epidemiologic study of 2071 patients and a review of the literature. Arch Dermatol 1991; 127: 1684-8.
7. Ragin CC, Modugno F, Gollin SM. The epidemiology and risk factors of head and neck cancer: a focus on human papillomavirus. J Dent Res 2007; 86: 104-14.
8. O'Neill LA. Signal transduction pathways activated by the IL-1 receptor/Toll-like receptor super family. Curr Top Microbiol Immunol 2002; 270: 47-61.
9. Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol 2005; 17: 1-14.
10. Ruan M, Zun Z, Siyi L, Wenjun Y, Lizheng W, Chenping Z. Increased expression of Toll-like receptor-9 has close relation with tumour cell proliferation in oral squamous cell carcinoma. Arch Oral Biol 2011; 56: 877-84.
11. Sdek P, Zhang ZY, Cao J, Pan HY, Chen WT, Zheng JW. Alteration of cell-cycle regulatory proteins in human oral epithelial cells immortalized by HPV16 E6 and E7. Int J Oral Maxillofac Surg 2006; 35: 653-7.
12. Zhong LP, Pan HY, Zhou XJ et al. Characteristics of a cancerous cell line, HIOEC-B(a)P-96, induced by benzo(a)pyrene from human immortalized oral epithelial cell line. Arch Oral Biol 2008; 53: 443-52.
13. Jin X, Song X, Li L et al. Blockade of AP-1 activity by dominant-negative TAM67 can abrogate the oncogenic phenotype in latent membrane protein 1-positive human nasopharyngeal carcinoma. Mol Carcinog 2007; 46: 901-11.
14. Medeiros LJ, Hai S, Thomazy VA, Estalilla OC, Romaguera J, Luthra R. Real-time RT-PCR assay for quantifying cyclin D1 mRNA in B-cell non-Hodgkin's lymphomas. Mod Pathol 2002; 15: 556-64.
15. Min R, Tong J, Wenjun Y et al. Growth inhibition and induction of apoptosis in human oral squamous cell carcinoma Tca-8113 cell lines by Shikonin was partly through the inactivation of NF-κB pathway. Phytother Res 2008; 22: 407-15.
16. Zhou X, Zhang Z, Yang X, Chen W, Zhang P. Inhibition of cyclin D1 expression by cyclin D1 shRNAs in human oral squamous cell carcinoma cells is associated with increased cisplatin chemosensitivity. Int J cancer 2009; 124: 483-9.
17. Lin CW, Hou WC, Shen SC et al. Quercetin inhibition of tumor invasion via suppressing PKC delta/ERK/AP-1-dependent matrix metalloproteinase-9 activation in breast carcinoma cells. Carcinogenesis 2008; 29: 1807-15.
18. Kaomongkolgit R, Cheepsunthorn P, Pavasant P, Sanchavanakit N. Iron increases MMP-9 expression through activation of AP-1 via ERK/Akt pathway in human head and neck squamous carcinoma cells. Oral Oncol 2008; 44: 587-94.
19. Toualbi-Abed K, Daniel F, Güller MC et al. Jun D cooperates with p65 to activate the proximal kB site of the cyclin D1 promoter: role of PI3K/PDK-1. Carcinogenesis 2008; 29: 536-43.
20. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
21. Knudsen KE, Diehl JA, Haiman CA, Knudsen ES. Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene 2006; 25: 1620-8.
22. Bartkova J, Lukas J, Muller H, Strauss M, Gusterson B, Bartek J. Abnormal patterns of D-type cyclin expression and G1 regulation in human head and neck cancer. Cancer Res 1995; 55: 949-56.
23. Akervall JA, Michalides RJ, Mineta H et al. Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 overexpression. Cancer 1997; 79: 380-9.
24. Rousseau A, Lim MS, Lin Z, Jordan RC. Frequent cyclin D1 gene amplification and protein overexpression in oral epithelial dysplasias. Oral Oncol 2001; 37: 268-75.
25. Shintani S, Mihara M, Nakahara Y et al. Expression of cell cycle control proteins in normal epithelium, premalignant and malignant lesions of oral cavity. Oral Oncol 2002; 38: 235-43.
26. Shen Q, Uray IP, Li Y et al. The AP-1 transcription factor regulates breast cancer cell growth via cyclins and E2F factors. Oncogene 2008; 27: 366-77.
27. Klein EA, Assoian RK. Transcriptional regulation of the cyclin D1 gene at a glance. J Cell Sci 2008; 121: 3853-7.
28. Mishra A, Bharti AC, Saluja D, Das BC. Transactivation and expression patterns of Jun and Fos/AP-1 super-family proteins in human oral cancer. Int J Cancer 2010; 126: 819-29.
29. Rao SK, Pavicevic Z, Du Z et al. Pro-inflammatory genes as biomarkers and therapeutic targets in oral squamous cell carcinoma. J Biol Chem 2010; 285: 32512-21.
30. Ouafik L, Berenguer-Daize C, Berthois Y. Adrenomedullin promotes cell cycle transit and up-regulates cyclin D1 protein level in human glioblastoma cells through the activation of c-Jun/JNK/AP-1 signal transduction pathway. Cell Signal 2009; 21: 597-608.
31. Yuspa SH. The pathogenesis of squamous cell cancer: lessons learned from studies of skin carcinogenesis-thirty-third G.H.A. Clowes memorial award lecture. Cancer Res 1994; 54: 1178-89.
32. Li JJ, Westergaard C, Ghosh P, Colburn NH. Inhibitors of both nuclear factor-kappaB and activator protein-1 activation block the neoplastic transformation response. Cancer Res 1997; 57: 3569-76.
33. Thompson EJ, Gupta A, Stratton MS, Bowden GT. Mechanism of action of a dominant negative c-jun mutant in inhibiting activator protein-1 activation. Mol Carcinog 2002; 35: 157-62.
34. Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 2003; 3: 859-68.
35. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS Jr. NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 1999; 19: 5785-99.
36. Myo K, Uzawa N, Miyamoto R, Sonoda I, Yuki Y, Amagasa T. Cyclin D1 gene numerical aberration is a predictive marker for occult cervical lymph node metastasis in TNM Stage I and II squamous cell carcinoma of the oral cavity. Cancer 2005; 104: 2709-16.
37. Mishra R, Das BR. Cyclin D1 expression and its possible regulation in chewing tobacco mediated oral squamous cell carcinoma progression. Arch Oral Biol 2009; 54: 917-23.
38. Kundu SD, Lee C, Billips BK et al. The toll-like receptor pathway: a novel mechanismof infection-induced carcinogenesis of prostate epithelial cells. Prostate 2008; 68: 223-9.
39. Di JM, Pang J, Sun QP et al. Toll-like receptor 9 agonists up-regulates the expression of cyclooxygenase-2 via activation of NF-κB in prostate cancer cells. Mol Biol Rep 2010; 37: 1849-55.